Vanguard Group Inc. Sells 19,274 Shares of Bio-Rad Laboratories, Inc. $BIO

Vanguard Group Inc. decreased its position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 1.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,774,263 shares of the medical research company's stock after selling 19,274 shares during the quarter. Vanguard Group Inc. owned approximately 6.58% of Bio-Rad Laboratories worth $537,584,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in BIO. Royal Bank of Canada raised its holdings in Bio-Rad Laboratories by 25.2% in the first quarter. Royal Bank of Canada now owns 30,310 shares of the medical research company's stock worth $7,382,000 after purchasing an additional 6,100 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Bio-Rad Laboratories by 45.6% in the first quarter. Goldman Sachs Group Inc. now owns 105,006 shares of the medical research company's stock worth $25,575,000 after purchasing an additional 32,874 shares in the last quarter. Empowered Funds LLC increased its holdings in shares of Bio-Rad Laboratories by 14.8% during the first quarter. Empowered Funds LLC now owns 1,547 shares of the medical research company's stock valued at $377,000 after acquiring an additional 199 shares in the last quarter. Jane Street Group LLC increased its holdings in shares of Bio-Rad Laboratories by 95.3% during the first quarter. Jane Street Group LLC now owns 37,383 shares of the medical research company's stock valued at $9,105,000 after acquiring an additional 18,239 shares in the last quarter. Finally, Cetera Investment Advisers increased its holdings in shares of Bio-Rad Laboratories by 13.5% during the second quarter. Cetera Investment Advisers now owns 2,192 shares of the medical research company's stock valued at $529,000 after acquiring an additional 260 shares in the last quarter. Institutional investors own 65.24% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on BIO shares. Wells Fargo & Company reduced their price target on Bio-Rad Laboratories from $320.00 to $290.00 and set an "equal weight" rating for the company in a report on Friday. Citigroup downgraded Bio-Rad Laboratories from a "buy" rating to a "neutral" rating and reduced their price target for the company from $375.00 to $300.00 in a report on Tuesday, April 7th. Finally, Wall Street Zen downgraded Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Saturday, February 14th. One research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Bio-Rad Laboratories has an average rating of "Hold" and an average price target of $333.00.

Bio-Rad Laboratories Price Performance

Shares of NYSE:BIO opened at $257.80 on Tuesday. Bio-Rad Laboratories, Inc. has a 1-year low of $211.43 and a 1-year high of $343.12. The business has a fifty day moving average price of $277.81 and a 200-day moving average price of $298.11. The company has a market capitalization of $6.96 billion, a PE ratio of 42.47 and a beta of 1.06. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.21 and a quick ratio of 2.37.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $1.89 EPS for the quarter, missing the consensus estimate of $1.97 by ($0.08). Bio-Rad Laboratories had a return on equity of 3.56% and a net margin of 6.52%.The business had revenue of $592.10 million during the quarter, compared to the consensus estimate of $589.91 million. During the same quarter in the previous year, the business posted $2.54 earnings per share. Bio-Rad Laboratories's quarterly revenue was up 1.1% compared to the same quarter last year. As a group, equities analysts expect that Bio-Rad Laboratories, Inc. will post 10.32 EPS for the current fiscal year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.